FAPESP
SÃO PAULO RESEARCH FOUNDATION

UNICAMP

SGC

New Horizons in Medicinal Chemistry of Protein Kinases

CBMEG
CENTRO DE BIOLOGIA MOLECULAR E ENGENHARIA GENÉTICA

IB
Instituto de Biologia

1:00 Opening Session: **Eduardo Moacyr Krieger**, (FAPESP), **Opher Gileadi** (SGC), **Paulo Arruda** (UNICAMP), **Sergio Queiroz**, FAPESP

1:15 **Stefan Knapp** Goethe Universitat, Frankfurt, GER

Targeting catalytic and non-catalytic functions of protein kinases

1:45 **Marcus Smolka**, Cornell University, USA

Probing kinase action and inhibition in vivo

2:15 **Cristiano R.W. Guimarães** Aché Pharmaceutical Laboratories, BR

Research, Development and (Open) Innovation at Aché: Exploring understudied kinases with the Structural Genomics Consortium

2:45 Break

3:00 **Jon Elkins**, SGC, Oxford

Using old inhibitors to start chemical probe development on new targets: NAK family kinases

3:30 **Stefan Laufer**, University of Tubingen, GER

The glycine flip strategy for generation of selective kinase inhibitors

4:00 **Panel discussion**: Why aren't there kinase-targeting drugs for every disease?

Mediator: **Amy Donner**

Panelists: **John Mathias** (Pfizer), **Kumar Saikatendu** (Takeda**), David Drewry** (SGC), **Saul Rosenberg** (Abbvie)

5:00 **Aled Edwards,** Structural Genomics Consortium, University of Toronto, CA

Closing remarks

Protein kinases







Protein kinases

The human kinome





Fedorov et al. (2010) Nat Chem Biol. 6:166-169.

SGC

A public-private partnership that supports the discovery of new medicines through open access research

www.thesgc.org

SGC

wellcome trust Strategic Award
Ontario
gsk GlaxoSmithKline
NOVARTIS
Pfizer
Boehringer Ingelheim
GenomeCanada
Takeda
abbvie
janssen
Lilly
BAYER
FAPESP SÃO PAULO RESEARCH FOUNDATION
UNICAMP
UNIVERSITY OF TORONTO
UNIVERSITY OF OXFORD
UNC ESHELMAN INSTITUTE FOR INNOVATION

About The SGC

The SGC is an international public-private partnership (UK charity number 1097737) that aims to carry out basic science of relevance to drug discovery, placing all information, reagents and know-how into the public domain without restriction.

www.thesgc.org

ACKNOWLEDGEMENTS

SGC-UNICAMP
Paulo Arruda
Katlin Massirer

Nathalia Zocal

SGC-UNC
Tim Willson
Bill Zuercher

Speakers
Stefan Knapp
Marcus Smolka
Cristiano R.W. Guimarães
Jon Elkins
Stefan Laufer
Any Donner
John Mathias
Kumar Saikatendu
David Drewry
Saul Rosenberg

Funding partners:
AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Genome Canada, GlaxoSmithKline, the Innovative Medicines Initiative, Janssen, Lilly Canada, Merck & Co., the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, the São Paulo Research Foundation, Takeda, and the Wellcome Trust.

www.thesgc.org

1:00 Opening Session: **Eduardo Moacyr Krieger**, (FAPESP), **Opher Gileadi** (SGC), **Paulo Arruda** (UNICAMP), **Sergio Queiroz**, FAPESP

1:15 **Stefan Knapp** Goethe Universitat, Frankfurt, GER

Targeting catalytic and non-catalytic functions of protein kinases

1:45 **Marcus Smolka,** Cornell University, USA

Probing kinase action and inhibition in vivo

2:15 **Cristiano R.W. Guimarães** Aché Pharmaceutical Laboratories, BR

Research, Development and (Open) Innovation at Aché: Exploring understudied kinases with the Structural Genomics Consortium

2:45 Break

3:00 **Jon Elkins**, SGC, Oxford

Using old inhibitors to start chemical probe development on new targets: NAK family kinases

3:30 **Stefan Laufer**, University of Tubingen, GER

The glycine flip strategy for generation of selective kinase inhibitors

4:00 **Panel discussion**: Why aren't there kinase-targeting drugs for every disease?

Mediator: **Amy Donner**

Panelists: **John Mathias** (Pfizer), **Kumar Saikatendu** (Takeda**), David Drewry** (SGC), **Saul Rosenberg** (Abbvie)

5:00 **Aled Edwards,** Structural Genomics Consortium, University of Toronto, CA

Closing remarks